Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 monotherapy dose-escalation study in myelofibrosis
ACTRN12608000614392Phase 2Completed
- Sponsor
- Consorzio Mario Negri Sud
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in myelofibrosis (MF), sponsored by Consorzio Mario Negri Sud. Primary endpoint: Maximum tolerated dose based on dose-limiting toxicity. Started Oct 2008; status: completed.
02
Drugs
everolimus
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ACTRN12608000614392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000614392.